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  ChilDRen’S oRthoPaeDiCS
The Forearm Fracture Recovery in 
Children Evaluation (FORCE) trial: 
statistical and health economic analysis 
plan for an equivalence randomized 
controlled trial of treatment for torus 
fractures of the distal radius in children
aims
Torus fractures of the distal radius are the most common fractures in children. The NICE non- 
complex fracture guidelines recently concluded that bandaging was probably the optimal 
treatment for these injuries. However, across the UK current treatment varies widely due to 
a lack of evidence underpinning the guidelines. The Forearm Fracture Recovery in Children 
Evaluation (FORCE) trial evaluates the effect of a soft bandage and immediate discharge 
compared with rigid immobilization.
Methods
FORCE is a multicentre, parallel group randomized controlled equivalence trial. The primary 
outcome is the Wong- Baker FACES pain score at three days after randomization and the prima-
ry analysis of this outcome will use a multivariate linear regression model to compare the two 
groups. Secondary outcomes are measured at one and seven days, and three and six- weeks 
post- randomization and include the Patient Reported Outcome Measurement Information Sys-
tem (PROMIS) upper extremity limb score, EuroQoL EQ- 5D- Y, analgesia use, school absence, 
complications, and healthcare resource use. The planned statistical and health economic anal-
yses for this trial are described here. The FORCE trial protocol has been published separately.
Conclusion
This paper provides details of the planned analyses for this trial, and will reduce the risks of 
outcome reporting bias and data driven results.
Cite this article: Bone Joint Open 2020;1-6:205–213.
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introduction
Torus (buckle) fractures of the distal radius 
are the most common fractures in children, 
accounting for 500,000 UK emergency 
attendances annually.1 Children’s bones are 
very flexible compared with adult bones, and 
can ‘buckle’ such that there is deformation 
but no break in the cortex. Torus fractures 
are very low risk injuries for complication 
or deformity in the skeletally immature, and 
these fractures universally heal well.2
There is considerable variation in the 
management of torus fractures, with treat-
ment varying from the use of a removable 
splint, to plaster cast immobilization, to more 
flexible splints. The variation in practice has 
arisen from a longstanding taught doctrine of 
rigid immobilization for fractures,3 tempered 
with newer evidence to suggest that simpler 
treatment methods are frequently as effective 
or perhaps even more effective.4-8 Two system-
atic reviews support the abandonment of 
non- removable rigid casts in favour of splints 
removable at home.9,10 The first of these identi-
fied eight studies, including 825 participants in 
total, and highlighting several benefits of alter-
native types of splints over casts.9 The second 
review included eight randomized controlled 
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trials (RCTs) (781 participants in total), demonstrated a 
variety of benefits of non- rigid immobilization, and showed 
patients would like to choose non- rigid methods of immo-
bilization for future use.10
The recent niCE non- complex fracture guidelines made 
recommendations on the management of these injuries,1 
concluding that torus fractures of the distal radius should 
not be immobilized in a non- removable rigid cast, and 
advocating discharge from the emergency department 
without subsequent need for outpatient follow- up. niCE 
recommended that bandaging or soft casts should be the 
mainstay of treatment for torus fractures but questioned 
whether any intervention was necessary at all.
The best evidence for minimal immobilization for the 
treatment of torus fractures of the distal radius comes 
from the use of soft bandaging in two small, low- quality 
randomized trials comparing soft bandaging to rigid 
plaster casts.11,12 These trials identified improved pain, 
improved function, less school absence and better conve-
nience with bandaging, although there was a degree of 
parental anxiety about not using a splint/cast to treat 
a broken bone. There have been no trials comparing 
removable rigid splints to bandage treatment.
The FORCE study is a randomized equivalence trial of 
soft bandage versus immobilization with splints as per 
current practice. The protocol paper for FORCE is also 
published separately in this journal;13 the aim of this 
paper is to report in detail the statistical analysis plan as 
reviewed by the trial steering committee and the plan 
for the health economics analysis. This paper has been 
prepared according to the published guidelines on the 
content of statistical analysis plans14 and the guidance on 
how to conduct economic evaluations alongside RCTs.15,16
Methods
trial design. FORCE is a multicentre, two- arm, parallel 
group, randomized, controlled, equivalence trial compar-
ing offer of a soft bandage and immediate discharge with 
splint immobilization and follow- up as per the protocol 
of the treating centre for the treatment of torus fractures 
of the distal radius in children. Children aged four to 15 
years who have sustained a torus fracture within the last 
36 hours, show no cortical disruption on radiographs, 
and have no additional fractures (other than ipsilater-
al ulna fractures) are eligible for this study. Eligible pa-
tients are randomized on a 1:1 basis to the two treatment 
groups. Randomization is stratified by recruitment centre 
and by age group (four to seven- year- olds versus eight to 
15- year- olds). The nature of treatments used means that 
participants, their parents/guardians, and their treating 
clinicians cannot be blind to treatment allocation. The 
primary outcome is the Wong- Baker FACES pain rating 
scale17 measured at three days post- randomization. The 
feasibility of collecting this outcome electronically was 
established in a feasibility study.18 Secondary outcomes 
are assessed at one, three and seven days, and three and 
six weeks post- randomization. All data collection is per-
formed electronically, and participants and their parents/
guardians are prompted to complete follow- ups via text 
and/or email. Full details of the trial design, study popu-
lation, and study procedures are published separately.13
objectives. The primary objective of this trial is to quan-
tify and draw inferences on observed differences in the 
Wong- Baker FACES pain rating scale at three days post- 
randomisation between children allocated to soft band-
age and immediate discharge and those allocated to rigid 
immobilization and standard follow- up. Secondary ob-
jectives include assessing differences between the same 
groups in Wong- Baker FACES, Patient Reported Outcome 
Measurement information System (PROMiS) upper ex-
tremity limb scores, EQ- 5D- Y scores, days of school ab-
sence, complications, and resource use up to six weeks 
post- randomization, and differences in regular analgesia 
use up to seven days post- randomization.
outcomes
Primary outcome. The primary outcome measure in this 
trial is the Wong- Baker FACES pain rating scale.17 This is a 
validated, self- reported tool consisting of an ordinal as-
sessment of pain using six facial expressions to illustrate 
the degree of pain intensity (from 0 “no hurt” to 10 “hurts 
worst”) with each face equating to 2 points on the scale. 
This is self- reported by all participants. This scale will be 
measured at baseline, one, three, and seven days, and 
three and six weeks post- randomization, with three days 
being the primary endpoint.
Secondary outcomes. The secondary outcome measures 
are as follows:
 PROMiS upper extremity limb score for children:19,20 
this measures the functional recovery of upper limb 
function. This will be delivered as a computer adap-
tive test (CAT), with each participant answering an 
average of eight questions. A CAT enables the answer 
from one question to inform the choice of the next, 
so that each child may answer a distinct set of ques-
tions to reach their score. PROMiS scores will be self- 
reported by participants aged eight to 15 years, and 
proxy- reported for those aged four to seven years. 
This is measured at baseline, three, and seven days, 
and three and six weeks post- randomization.
  Analgesia use: whether or not participants have used 
analgesia in the last 24 hours, and details of the type 
of analgesia used, will be recorded at one, three, and 
seven days post- randomization.
  Euroqol EQ- 5D- Y:21,22 the youth version of the 
EQ- 5D- 3L, which consists of five domains related 
to daily activities, each with three possible answers. 
This will be self- reported by participants aged eight 
to 15 years, and proxy- reported for the younger age 
group (four to seven years). it is measured at baseline, 
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table i. Summary of outcomes and assessment schedule.
assessment
timing
Baseline 1 day 3 days 7 days 3 weeks 6 weeks
Demographic 
details
✓
injury details ✓
treatment 
details
✓
Wong- Baker 
FaCeS
✓ ✓ ✓ ✓ ✓ ✓
PRoMiS upper 
extremity limb 
score
✓ ✓ ✓ ✓ ✓
eQ- 5D- Y ✓ ✓ ✓ ✓ ✓
Satisfaction ✓ ✓
Use of analgesia ✓ ✓ ✓
Use of 
immobilization
✓ ✓ ✓ ✓
Complications ✓ ✓ ✓ ✓ ✓
Days school 
absence
✓ ✓
Resource use ✓ ✓
three, and seven days, and three and six weeks 
post- randomization.
  Days of absence from school/childcare because of 
the injury: this is measured where applicable. This is 
proxy- reported for all participants. Data on absence 
in the preceding 21 days is collected at three and six 
weeks post- randomization.
  Complications: all complications are recorded, with 
particular note made of hospital re- attendance for 
any reason including inadequate analgesia, refrac-
ture, or worsening of the fracture. These will be 
proxy- reported for all participants with additional 
information provided by clinical teams as necessary.
 Healthcare utilization: nHS costs and patients’ 
parent’s out- of- pocket expenses are recorded via a 
short questionnaire administered at three and six 
weeks post- randomization.
The data collected at each time point are summarized in 
Table i.
Sample size
The primary outcome in this study is the six- point Wong- 
Baker FACES pain rating scale at three days. The Wong- 
Baker scale has a minimum clinically important difference 
(MCiD) of 1 face which equates to 2 points on the numer-
ical scale.23 This trial aims to demonstrate the equivalence 
of a soft bandage compared with rigid immobilization. 
Assuming an equivalence margin of 1 point (half the 
MCiD), 90% power, one- sided 2.5% significance, and 
that the standard deviation (SD) is 2.3 (based on a feasi-
bility study), 278 participants (139 per arm) would be 
required to show equivalence. The Wong- Baker scale is 
a categorical outcome that is more likely to be non- linear 
in younger age groups, tending to linearity in those over 
eight years of age. 24 Therefore, the trial is powered sepa-
rately for equivalence in the two subpopulations (four 
to seven- year- olds and eight to 15- year- olds). in all, 278 
participants in the four to seven years age group and 
278 participants in the eight to 15 years age group are 
needed to show equivalence.
Allowing for 20% loss to follow- up inflates the required 
sample size to 348 in each of the sub- populations (174 
per arm). Given the primary outcome is at three days 
post randomization, the loss to follow- up inflation can 
be readily adjusted to ensure that the study recruits effec-
tively and efficiently.
Statistical analysis
General analysis principles. Two analysis populations will 
be considered, the intent- to- treat (iTT) population and 
the per- protocol (PP) population. The iTT population will 
include all participants randomized, and participants will 
be analyzed according to the group to which they were 
randomized regardless of the treatment they actually re-
ceived. The PP population will be analyzed according to 
the treatment they actually received. Participants will be 
excluded from the PP population if: i) they did not re-
ceive the treatment to which they were randomized, or 
changed from their allocated treatment prior to the pri-
mary outcome time point (three days); ii) they did not 
provide sufficient follow- up data for analysis; or, iii) they 
did not satisfy the eligibility criteria for the study. Exact 
exclusion criteria for the PP analysis will be confirmed 
based on a blinded analysis of the data (not separated by 
treatment group) prior to the final data lock.
As this is an equivalence trial, a maximum clinical 
difference (ΔT) has been prespecified for the primary 
outcome. This specifies the level within which the two 
treatments can be considered not to differ in any clinically 
meaningful way. The null hypothesis we are testing in 
this trial is that a difference greater than ΔT exists between 
the treatments in either direction. The trial is designed to 
disprove this in favour of the alternative that no clinical 
difference exists. Analyses of the primary outcome will be 
carried out on the iTT population and repeated for the PP 
population and only if both results show equivalence will 
equivalence be claimed.25,26
Analyses of all secondary outcomes will be performed 
for the iTT population and repeated for the PP population.
The significance level used will be 0.05 with 95% confi-
dence intervals (Cis) reported. All secondary analyses will 
be considered as supporting the primary outcome anal-
ysis and will also be analyzed using a significance level of 
0.05 with 95% Cis reported.
To ensure consistency, validation checks of the data 
will be conducted. As the data is collected electroni-
cally, many of these checks will be implemented auto-
matically as part of the data entry procedure. Analysis 
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Fig. 1
COnSORT flow diagram for participants in trial up to six weeks follow- up.
of the primary (Wong- Baker FACES) and key secondary 
(PROMiS) outcomes will be independently repeated by a 
statistician not involved in the trial to validate the results.
All analyses will be carried out using appropriate, vali-
dated statistical software such as STATA27 or R.28 The rele-
vant package and version number used for the analysis 
will be recorded and reported.
Descriptive analyses. The flow of participants through 
each stage of the trial, including the number of individu-
als screened, eligible, randomized to each arm, receiving 
allocated treatment, and included in the primary analysis 
will be summarized using a COnSORT flowchart (Fig. 1). 
Reasons for ineligibility, loss to follow- up and exclusion 
from the primary analysis will be summarized. The data 
will be summarized separately for the two age groups 
(four- to seven- year- olds and eight- to 15- year- olds).
The baseline comparability of the two randomized 
groups in terms of: i) stratification factors; ii) baseline 
characteristics (Table  ii); and iii) primary and secondary 
outcomes at baseline, will be presented. numbers with 
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table ii. Baseline characteristics.
Baseline characteristic type levels or scale
Sex Binary Male; Female
Age Continuous Years
Side of injury Binary Right; Left
Mechanism of injury Categorical Low energy fall; High energy fall; 
Other
Dominant hand Categorical Right; Left; Unsure/ambidextrous
percentages will be used to compare binary and categor-
ical variables, and either means and SDs or medians and 
interquartile ranges (iQRs) will be used for continuous 
variables. There will be no tests of statistical significance 
nor Cis for differences at baseline between the random-
ized groups.
loss to follow-up, withdrawals, and missing data. The num-
bers (and percentages) of losses to follow- up and with-
drawals along with reasons for these will be reported by 
treatment group at each time point. if differential losses are 
identified the reasons for these will be explored further. no 
deaths are anticipated in this study; however, if any do oc-
cur these will be reported separately together with reasons.
The number and percentage of individuals with 
missing data for each outcome at each time point will 
be summarized by treatment group, along with reasons 
for missing- ness if known. The patterns of missing- ness 
will also be explored and the suitability of missing data 
assumptions considered.
All the main analyses in this trial will be performed 
using the available case dataset. Since the primary 
outcome time point is three days after randomization, 
it is not anticipated that there will be a high volume of 
missing data. in addition, the multi- level model using 
repeated measures which is planned as one of the 
supporting analyses of the primary outcome is relatively 
robust to missing data under the missing at random 
(MAR) assumption.29 However, if more than 10% of the 
data is missing, then sensitivity analyses exploring a 
variety of missing not at random scenarios will be under-
taken to ensure the results are robust to departures from 
the MAR assumption. no imputation is planned for any 
of the secondary outcomes.
Compliance. The numbers and percentages of partic-
ipants who: i) received their allocated treatment (splint 
immobilization or offer of a bandage) throughout/until 
removal of treatment; ii) received another treatment at 
baseline; iii) received their allocated treatment at baseline 
but changed to another treatment prior to the primary 
outcome time point (three days); and, iv) received their 
allocated treatment at baseline but changed to another 
treatment after the primary outcome time point, will be 
summarized by treatment group. Reasons for not receiv-
ing the allocated treatment, or for changing from the al-
located treatment will also be summarized.
For those receiving splint immobilization (either as 
their allocated treatment or as a deviation from their allo-
cated treatment), the number and percentage receiving 
each type of immobilization will be summarized as well 
as the average length of time the splint is worn. For those 
who are offered a bandage, details on the number and 
percentage who have this applied prior to discharge and 
who take it home and apply it at home will be summa-
rized. The average length of time the bandage is worn 
will also be summarized.
analysis of primary outcome. Wong- Baker FACES scores 
at three days after randomization will be summarized by 
treatment group using means and SDs. A multivariate 
linear regression model adjusting for stratification factors 
(age and recruitment centre) and participant sex will be 
used to compare the two groups. The appropriateness of 
the assumption of approximate normality of the residuals 
of this model will be assessed graphically. The adjusted 
difference between treatment groups will be reported 
along with associated 95% Cis and p- values. This analy-
sis will be performed for the iTT population and repeat-
ed for the PP population both using available cases, and 
only if both results show equivalence will equivalence be 
claimed. An unadjusted t- test will also be performed.
These analyses will be repeated separately for the 
two age groups (four to seven- year- olds and eight to 
15- year- olds) with results reported in a similar manner. 
Separate analyses for the two subgroups, instead of the 
inclusion of an interaction effect, will allow the treatment 
effects in the two subgroups to be considered separately. 
This may be important because the Wong- Baker score 
may behave differently in the two age groups; non- linear 
in younger children but tending to linearity in those over 
eight. The trial has been powered accordingly.
in addition, the analysis will be repeated to explore the 
impact of receipt of pain medication prior to this time 
point. This will involve repeating the analysis separately 
for the subgroups, or using seemingly unrelated regres-
sion30 as appropriate.
Analyses utilizing all time points (baseline to six 
weeks) will also be undertaken. Multi- level linear regres-
sion models using repeated measures (level 1) nested 
within participants (level 2) and adjusted for recruitment 
centre (level 3) and participant sex and age (fixed effects) 
will be used. Trends over time will be examined, and, if 
appropriate, interactions between treatment and time 
will be included in the model. The appropriateness of 
the assumption of approximate normality of the residuals 
of the model will be assessed graphically. Wong- Baker 
FACES scores at each time point will be summarized by 
treatment group using means and SDs and the adjusted 
difference between these will be reported along with the 
associated 95% Ci.
in addition, supplementary analyses using the area 
under the curve (AUC) summary statistics31 will be 
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conducted to investigate total pain: i) from baseline to 
three days after randomization; and ii) from baseline to 
six weeks after randomization. Parameter estimates from 
the mixed effects model will be used to calculate AUCs 
for each treatment group providing an overall estimate 
of pain over each time period (up to three days and up to 
six weeks). These will be presented with associated 95% 
Cis. The difference between the groups will be calculated 
and compared using a t- test.
if the assumption of approximate normality is not 
appropriate, the first approach will be to consider a trans-
formation of the data to attain normality. if normality 
cannot be achieved by transformation, the data will be 
analyzed separately for each time point using a non- 
parametric equivalent with no adjustment and medians 
and iQRs will be reported for each treatment group.
analysis of secondary outcomes. Continuous secondary 
outcomes (PROMiS and EQ- 5D- Y utility and VAS) will be 
analyzed using repeated measures mixed effects multi- 
level linear regression models similar to that outlined 
above. Scores at each time point will be summarized by 
treatment group using means and SDs and the adjust-
ed difference between these will be reported along with 
the associated 95% Ci. if the assumption of approximate 
normality is found not to be appropriate, the methods 
outlined earlier will be implemented.
The number and percentage of participants using 
pain medication in the first 7 days after randomization 
will be summarized by treatment group. A mixed effects 
logistic regression model adjusted for recruiting centre 
and participant sex and age will be used to compare the 
two treatment groups, and the adjusted odds ratio (OR) 
and associated 95% Ci will be reported. Risk differences 
and associated 95% Cis will also be reported. Trends over 
time by treatment group will be presented graphically. 
Any participants receiving something other than stan-
dard ‘over- the- counter’ pain- killers will be summarized.
The number and percentage of participants who have 
missed school up to 6 weeks after randomization will be 
similarly summarized and analyzed. The number of days 
of school missed will also be summarized by treatment 
group using medians and iQRs, and the two arms will be 
compared using non- parametric methods.
Since PROMiS scores, EQ- 5D- Y scores and use of pain 
medication are proxy- reported for the younger age group 
and patient- reported for the older age group, the analyses 
of these outcomes will be repeated including an interaction 
between treatment group and age group. Models analo-
gous to those outlined previously will be used.
analysis of complications and Saes. The number and per-
centage of participants experiencing a foreseeable com-
plication (recall to hospital with a diagnosis of an alterna-
tive fracture pattern or worsening fracture deformity) will 
be summarized by treatment group. The total number 
of complications experienced in each arm will also be 
summarized. if there are sufficient numbers of compli-
cations, a mixed effects logistic regression model adjust-
ed for recruiting centre and participant age and sex will 
be used to compare the rates of complications between 
treatment groups and the odds ratio and 95% Ci will be 
reported. Risk differences and associated 95% Cis will 
also be reported. The number of participants experienc-
ing each type of complication will also be summarized 
by treatment group and, if there are sufficient numbers of 
any type of complications, the two groups will be com-
pared using a chi- squared test. if sufficient numbers of 
complications occur, temporal patterns will be explored 
graphically.
The number and percentage of participants experi-
encing an SAE in each treatment group will be summa-
rized and compared in a similar manner. The total number 
of SAEs in each arm will also be summarized.
Supplementary analysis. Within the rigid immobilization 
group there are two types of immobilization which can 
be used, splint or cast. An exploratory analysis investigat-
ing the effect of type of immobilization used on Wong- 
Baker scores at three days after randomization will be 
conducted. This analysis will only be performed if a suffi-
cient number of participants receive each type of immo-
bilization (at least 10% to each type).
health economics analysis
A within- trial cost- utility analysis with imputation will 
be conducted from an nHS and Personal Social Services 
(PSS) perspective using the FORCE study data over the 
period of six weeks.
Measurement of resource use. Resource use data for the 
economic evaluation will be collected during the trial 
period from online questionnaires sent to participants at 
three and six weeks after randomization. Questionnaires 
will capture resource use associated with torus fractures 
of the distal radius: included are the frequency of use 
of outpatient care, community care and social care ser-
vices. Questionnaires will also record private care (e.g. 
physiotherapy), direct medical costs (e.g. medications), 
direct non- medical costs (e.g. help with childcare) and 
indirect costs (i.e. carer absenteeism) associated with 
the injury. These health resource questionnaires will be 
completed by the participant, or on behalf of the partic-
ipant (the proxy, usually the participant’s parent/guard-
ian). The questionnaires will cover two survey periods; 
baseline to three weeks, and three weeks to six weeks 
post- randomization.
Valuation of health outcomes. An EQ- 5D- Y value set is 
currently not available for the UK.32 We will value EQ- 
5D- Y responses using the most appropriate valuation 
set available for the trial population at the time of anal-
ysis. A recent review of patterns and trends of measure-
ment and valuation of childhood health utilities33 reveals 
that 78.7% of the studies using EQ- 5D- Y used general 
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adult- derived tariffs whereas the rest did not provide 
any information about the tariff used. if necessary the 
adult EQ- 5D- 3L tariff will be applied, in which case we 
will undertake sensitivity analysis to make sure that trial 
findings are not sensitive to the valuation set chosen.34 
Quality- adjusted life years (QALYs) will be calculated as 
the area under the utility curve of EQ- 5D utility scores 
recorded at baseline, three, and seven days, and three 
and six weeks post- randomization data using the trap-
ezoidal rule.35
Valuation of direct medical costs. Unit costs for resource 
items will be sourced from the latest national sources 
such as the nHS Supply Chain catalogue36 and nHS refer-
ence costs.37 Unit costs for the different forms of immobi-
lization applied (futura splint, back- slab, soft cast full, soft 
cast splint, hard cast full and hard cast splint) and gauze 
bandage will be sourced from the latest nHS Supply 
Chain catalogue. Since the injury is primarily managed 
solely within the Accident and Emergency department, 
the cost of hospitalisation as defined by the Health 
Resource Group (HRG) code is expected to be the same 
between the trial arms, as will be the unit cost for labour, 
the number and type of staff and duration of treatment. 
These data will be reported as part of the FORCE trial and 
included in the cost- utility analysis.
Sequelae resource use following trial interventions, 
such as outpatient care and community care, will be 
costed using the latest available nHS reference costs37 
and Personal Social Services Research Unit (PSSRU) 
costs.38 The unit cost of medication related to wrist injury 
will be sourced using the latest available British national 
Formulary (BnF) and the Prescription Cost Analysis (PCA) 
for England.39 Costs of medications for individual partic-
ipants will be estimated based on their reported doses 
and frequencies, when these are available, or reasonable 
average values when partially reported.
Valuation of direct non-medical and indirect costs. Patient 
non- medical costs will be obtained directly from the pa-
tient questionnaire. Parent or carer time off from work 
will be estimated using the daily median wage reported 
by the Office for national Statistics.40 These costs will be 
excluded from the base case analysis, limited to the nHS/
PSS perspective of the economic evaluation.
The patient- level cost of health resource use will be 
calculated by multiplying resource utilization by its unit 
cost. The base currency of all costs will be the most recent 
year for which unit cost data are available and expressed 
in UK pounds (£).
analysis of health economic outcomes. Within most trials 
some incompleteness of data is anticipated. Assuming 
missingness is non- trivial (5% or more), the base case 
analysis will use multiple imputation using the Mi suite of 
commands in Stata.27 The imputed within- trial incremen-
tal cost and quality- adjusted life years (QALYs) gained will 
be the base case, adjusted for trial stratification covariates. 
Complete case analysis will be reported as a sensitivity 
analysis.
imputation will follow good practice guidance41,42 
exploring the extent to which data are missing at random, 
for example by using logistic regression for missing-
ness of costs and QALYs against baseline variables.43 
Multiple imputed datasets (or ‘draws’) will be gener-
ated by treatment group, with missing values informed 
by regular (trial covariates) and imputed variables (costs 
and EQ- 5D- Y at each time point). To improve the robust-
ness of imputed values, predictive mean matching 
drawn from the five nearest neighbours will be used. 
The imputation model will use fully conditional (MCMC) 
methods (multiple imputation by chained equations), 
which manage missing and correlated data in multiple 
dependent variables. Each draw will be analyzed inde-
pendently using bivariate regression within the Stata Mi 
suite (StataCorp, College Station, Texas, USA), providing 
estimates adjusted for within and between variances 
for imputed samples.44 The number of draws will be set 
to minimize the information loss of finite imputation 
sampling – typically 20 draws. imputed and observed 
distributions will be compared visually and statistically to 
establish the consequences of estimation.
Within the Mi framework, seemingly unrelated regres-
sion equations (SUREG) will be used to model bivariate 
incremental changes in costs and QALYs. Baseline QOL 
scores will be included within models to allow for poten-
tial baseline imbalances.45 Joint distributions of costs and 
outcomes will be generated using the (non- parametric) 
bootstrap method, with replicates used to populate 
a cost- effectiveness plane. Using bias- corrected non- 
parametric bootstrapping, 5000 bootstraps will be taken 
per model or draw evaluated. Mean estimates will be 
reported with 95% Cis.
The incremental cost- effectiveness ratio (iCER) will be 
estimated as the difference between treatments in mean 
total costs divided by the difference in mean total QALYs 
within six weeks from intervention. Value- for- money is 
determined by comparing the iCER with a threshold value, 
typically the niCE threshold for British studies, of £20,000 to 
£30,000/QALY.46 Sensitivity analyses will include an explo-
ration of treatment interaction with the trial age strata.
The net monetary benefit (nMB) of changing treat-
ment will be reported as a recalculation of the iCER at 
a range of thresholds of willingness to pay for an addi-
tional QALY. The nMB describes the resource gain (or 
loss) when investing in a new treatment at a given will-
ingness to pay threshold. nMB estimates will be used to 
generate cost- effectiveness acceptability curves (CEACs). 
The CEAC compares the likelihood that treatments are 
cost- effective as the willingness to pay threshold varies.47
The expected value of perfect information (EVPi) is 
the upper limit of the value to a healthcare system of 
further research to eliminate uncertainty.48 Findings from 
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cost- effectiveness analyses remain uncertain because of 
the imperfect information they use. The nMB framework 
allows this expected cost of uncertainty to be determined 
and guide whether further research should be conducted 
to eliminate uncertainty.
Further cost analysis will be undertaken from a broader 
societal perspective. Reporting will follow the Consoli-
dated Health Economic Evaluation Reporting Standards 
(CHEERS) statement.49
Discussion
The FORCE trial will provide data regarding the effects of 
offer of a soft bandage on outcomes of participants up to 
six weeks after sustaining a buckle fracture, compared to 
those receiving rigid immobilization. This paper provides 
details of the planned analyses for this trial and will help 
reduce the risks of outcome reporting bias and data 
driven results.50
trial status
The trial opened to recruitment on 14 January 2019. 
Recruitment is currently ongoing, and is expected to 
finish by June 2020, with follow- up being completed by 
August 2020. The analysis of all primary and secondary 
outcomes will be conducted thereafter. These statis-
tical and health economic analysis plans were drafted, 
reviewed and finalised during the set- up and patient 
recruitment phases of the trial.
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